Press Releases Year None20212020201920182017 October 27, 2021 SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma PDF Version October 20, 2021 SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics PDF Version October 20, 2021 SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors PDF Version September 7, 2021 SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PDF Version August 30, 2021 SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version August 4, 2021 SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights PDF Version August 3, 2021 SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference PDF Version August 3, 2021 SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations PDF Version July 27, 2021 SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer PDF Version July 20, 2021 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041 PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page next › Last page last »
October 27, 2021 SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
October 20, 2021 SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics PDF Version
October 20, 2021 SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors PDF Version
September 7, 2021 SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PDF Version
August 30, 2021 SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version
August 4, 2021 SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights PDF Version
August 3, 2021 SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference PDF Version
August 3, 2021 SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations PDF Version
July 27, 2021 SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer PDF Version
July 20, 2021 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041 PDF Version
